These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9724849)

  • 1. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
    Levy Y; George J; Yona E; Shoenfeld Y
    Immunol Res; 1998 Aug; 18(1):55-60. PubMed ID: 9724849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3 nephritic factor and mesangiocapillary glomerulonephritis.
    Williams DG
    Pediatr Nephrol; 1997 Feb; 11(1):96-8. PubMed ID: 9035182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis.
    Power DA; Ng YC; Simpson JG
    Q J Med; 1990 Apr; 75(276):387-98. PubMed ID: 2385743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of nephritic factor as an immunoglobulin.
    Williams DG; Bartlett A; Duffus P
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system.
    Mathieson PW; Peters DK
    Nephrol Dial Transplant; 1997 Sep; 12(9):1804-6. PubMed ID: 9306323
    [No Abstract]   [Full Text] [Related]  

  • 7. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
    Habib R; Lévy M; Gubler MC; Broyer M; Habib M
    Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis.
    Ohi H; Watanabe S; Fujita T; Seki M; Hatano M
    J Immunol Methods; 1990 Jul; 131(1):71-6. PubMed ID: 2380570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Production of C3 nephritic factor by cultured lymphocytes derived from glomerulonephritic patients].
    Yamada A; Ohi H; Hatano M
    Nihon Jinzo Gakkai Shi; 1990 Apr; 32(4):373-8. PubMed ID: 2376910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis.
    Spitzer RE; Stitzel AE; Tsokos GC
    Clin Immunol Immunopathol; 1990 Oct; 57(1):10-8. PubMed ID: 1697516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome).
    Owen KR; Donohoe M; Ellard S; Clarke TJ; Nicholls AJ; Hattersley AT; Bingham C
    Nephron Clin Pract; 2004; 96(2):c35-8. PubMed ID: 14988595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
    Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
    Front Immunol; 2019; 10():886. PubMed ID: 31068950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease").
    Colville D; Guymer R; Sinclair RA; Savige J
    Am J Kidney Dis; 2003 Aug; 42(2):E2-5. PubMed ID: 12900843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleotide sequence of a human autoantibody to the alternative pathway C3/C5 convertase (C3NeF).
    Victor KD; Pascual V; Stitzel AE; Tsokos GC; Capra JD; Spitzer RE
    Hybridoma; 1993 Jun; 12(3):231-7. PubMed ID: 8395463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.